ES3060133T3 - Composition and method of treating cancer associated with egfr mutation - Google Patents

Composition and method of treating cancer associated with egfr mutation

Info

Publication number
ES3060133T3
ES3060133T3 ES19810149T ES19810149T ES3060133T3 ES 3060133 T3 ES3060133 T3 ES 3060133T3 ES 19810149 T ES19810149 T ES 19810149T ES 19810149 T ES19810149 T ES 19810149T ES 3060133 T3 ES3060133 T3 ES 3060133T3
Authority
ES
Spain
Prior art keywords
plinabulin
approximately
cancer
egfr
osimertinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19810149T
Other languages
English (en)
Spanish (es)
Inventor
Lan Huang
George Lloyd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeyondSpring Pharmaceuticals Inc
Original Assignee
BeyondSpring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BeyondSpring Pharmaceuticals Inc filed Critical BeyondSpring Pharmaceuticals Inc
Application granted granted Critical
Publication of ES3060133T3 publication Critical patent/ES3060133T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES19810149T 2018-06-01 2019-05-30 Composition and method of treating cancer associated with egfr mutation Active ES3060133T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862679619P 2018-06-01 2018-06-01
PCT/US2019/034726 WO2019232257A1 (en) 2018-06-01 2019-05-30 Composition and method of treating cancer associated with egfr mutation

Publications (1)

Publication Number Publication Date
ES3060133T3 true ES3060133T3 (en) 2026-03-25

Family

ID=68696755

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19810149T Active ES3060133T3 (en) 2018-06-01 2019-05-30 Composition and method of treating cancer associated with egfr mutation

Country Status (11)

Country Link
US (2) US20210161888A1 (cg-RX-API-DMAC7.html)
EP (1) EP3801524B1 (cg-RX-API-DMAC7.html)
JP (1) JP7500438B2 (cg-RX-API-DMAC7.html)
KR (1) KR102790127B1 (cg-RX-API-DMAC7.html)
CN (1) CN112543636B (cg-RX-API-DMAC7.html)
AU (1) AU2019278886B2 (cg-RX-API-DMAC7.html)
CA (1) CA3101612A1 (cg-RX-API-DMAC7.html)
DK (1) DK3801524T3 (cg-RX-API-DMAC7.html)
ES (1) ES3060133T3 (cg-RX-API-DMAC7.html)
MX (1) MX420412B (cg-RX-API-DMAC7.html)
WO (1) WO2019232257A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1249052A1 (zh) 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗与ras突变相关的癌症的方法
EP3334726B1 (en) 2015-07-13 2022-03-16 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
CN109475524A (zh) 2016-06-06 2019-03-15 万春药业公司 用于减少中性粒细胞减少症的组合物和方法
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20190109479A (ko) 2017-02-01 2019-09-25 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
WO2019147615A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
AU2022357570A1 (en) * 2021-10-03 2024-04-11 Systimmune, Inc. Methods of treating cancer and the pharmaceutical compositions thereof
CN117860672A (zh) * 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法
CN121311228A (zh) * 2023-06-02 2026-01-09 万春药业公司 肿瘤联合治疗和使用方法
CN120682197A (zh) * 2024-03-19 2025-09-23 大连万春布林医药有限公司 普那布林的盐晶型

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003302721B2 (en) * 2002-08-02 2009-10-08 Beyondspring Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US20120114658A1 (en) * 2009-09-15 2012-05-10 John Ryan Treatment of cancer
EA201200486A1 (ru) * 2009-09-15 2012-08-30 Серулин Фарма Инк. Лечение онкологических заболеваний
SG11201505896YA (en) * 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
MX394865B (es) * 2015-02-12 2025-03-24 Beyondspring Pharmaceuticals Inc Uso de plinabulina en combinación con inhibidores de punto de control inmunitario
HK1249052A1 (zh) * 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗与ras突变相关的癌症的方法
BR112019018880A2 (pt) * 2017-03-13 2020-04-14 Beyondspring Pharmaceuticals, Inc. composições de plinabulina e seu uso

Also Published As

Publication number Publication date
KR20210015875A (ko) 2021-02-10
AU2019278886B2 (en) 2025-03-20
JP2021525768A (ja) 2021-09-27
JP7500438B2 (ja) 2024-06-17
US20210161888A1 (en) 2021-06-03
CA3101612A1 (en) 2019-12-05
DK3801524T3 (da) 2026-02-02
MX420412B (es) 2025-02-10
WO2019232257A1 (en) 2019-12-05
AU2019278886A1 (en) 2020-12-24
CN112543636A (zh) 2021-03-23
MX2020012799A (es) 2021-03-25
KR102790127B1 (ko) 2025-04-03
EP3801524B1 (en) 2025-11-05
EP3801524A4 (en) 2022-03-02
US20250375440A1 (en) 2025-12-11
EP3801524A1 (en) 2021-04-14
CN112543636B (zh) 2024-03-01

Similar Documents

Publication Publication Date Title
US20250375440A1 (en) Composition and method of treating cancer associated with egfr mutation
JP6769982B2 (ja) Ras変異と関連するがんの治療方法
US20190134033A1 (en) Pharmaceutical combinations
JP2022520079A (ja) Tno155及びkrasg12c阻害剤を含む医薬組合せ
US20150202203A1 (en) Method of Treating Gastrointestinal Stromal Tumors
PT2637664T (pt) Composições e métodos de tratamento de hipertensão pulmonar
EP3010505A1 (en) Pharmaceutical combinations
US11413284B2 (en) Protein kinase C inhibitors for treatment of uveal melanoma
US20250041277A1 (en) Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer
EA029072B1 (ru) Комбинированная терапия, включающая соединение дигидропиразинопиразина и антагонист рецептора андрогена для лечения рака простаты
US20120045433A1 (en) Combination therapy
US9446043B2 (en) Pharmaceutical combinations
WO2023244639A1 (en) Methods of predicting cns cancer response to treatment with egfr inhibitors
EP4203963B1 (en) Combination therapy of naporafenib and trametinib for use in the treatment of sarcoma
KR20210084442A (ko) 포도막 흑색종 치료를 위한 병용 요법
EP4656193A1 (en) Pharmaceutical composition for treating tumors
HK40038993A (en) Composition and method of treating cancer associated with egfr mutation
HK1215789B (en) Pharmaceutical combinations
WO2017013271A1 (en) Combination of an inhibitor of phosphatidylinositol 3-kinase delta and a bcl-2 inhibitor, uses and pharmaceutical compositions thereof